Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
There is accumulating evidence that treatment of chronic hepatitis C (HCV) leads to improvements in liver fibrosis. We aimed to investigate the improvement in fibrosis stage following treatment with direct-acting antivirals (DAAs) and factors associated with fibrosis regression. Fibroscan<sup>...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/13/9/1872 |
| _version_ | 1797579181722173440 |
|---|---|
| author | Naim Abu-Freha Osama Abu-Kosh David Yardeni Yaffa Ashur Muhammad Abu-Arar Baha Yousef Shulamit Monitin Sarah Weissmann Ohad Etzion |
| author_facet | Naim Abu-Freha Osama Abu-Kosh David Yardeni Yaffa Ashur Muhammad Abu-Arar Baha Yousef Shulamit Monitin Sarah Weissmann Ohad Etzion |
| author_sort | Naim Abu-Freha |
| collection | DOAJ |
| description | There is accumulating evidence that treatment of chronic hepatitis C (HCV) leads to improvements in liver fibrosis. We aimed to investigate the improvement in fibrosis stage following treatment with direct-acting antivirals (DAAs) and factors associated with fibrosis regression. Fibroscan<sup>®</sup> was performed for patients treated with DAAs, at least 3 years post-HCV eradication. The fibrosis stage at the onset of treatment was compared with the current fibrosis stage. A total of 209 patients were enrolled in this study (56% males; age 58.8 ± 13.3 years; age at treatment 54 ± 10.9 years). Genotype subgrouping was as follows: 1a (16%), 1b (58%), 2a (4%), 3 (18%), and 4a (2%). Overall, 71% of patients were considered treatment-naïve, with a mean follow-up time of 4.5 ± 1.3 years. Fibrosis improvement was observed among 57% of patients; fibrosis progression was seen among 7% of patients and no change was seen in 36% of patients. Moreover, 28% of these patients regressed from F3/F4 to F2 or less. In our multivariable analysis, the age at treatment and advanced fibrosis stage were found to be factors significantly associated with fibrosis regression. In conclusion, fibrosis improvement was observed among 57% of HCV patients after treatment with DAAs. Age and advanced fibrosis at baseline were found to be factors associated with fibrosis regression. |
| first_indexed | 2024-03-10T22:33:16Z |
| format | Article |
| id | doaj.art-a90f5c126c714dd686e784f866a38be0 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T22:33:16Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-a90f5c126c714dd686e784f866a38be02023-11-19T11:37:28ZengMDPI AGLife2075-17292023-09-01139187210.3390/life13091872Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral AgentsNaim Abu-Freha0Osama Abu-Kosh1David Yardeni2Yaffa Ashur3Muhammad Abu-Arar4Baha Yousef5Shulamit Monitin6Sarah Weissmann7Ohad Etzion8Institute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, IsraelDivision of Internal Medicine, Soroka University Medical Center, Beer-Sheva 84101, IsraelInstitute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, IsraelMedical Management Unit, Soroka University Medical Center, Beer-Sheva 84101, IsraelDivision of Internal Medicine, Soroka University Medical Center, Beer-Sheva 84101, IsraelInstitute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, IsraelInstitute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, IsraelSoroka Clinical Research Center, Soroka University Medical Center, Beer-Sheva 84101, IsraelInstitute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, IsraelThere is accumulating evidence that treatment of chronic hepatitis C (HCV) leads to improvements in liver fibrosis. We aimed to investigate the improvement in fibrosis stage following treatment with direct-acting antivirals (DAAs) and factors associated with fibrosis regression. Fibroscan<sup>®</sup> was performed for patients treated with DAAs, at least 3 years post-HCV eradication. The fibrosis stage at the onset of treatment was compared with the current fibrosis stage. A total of 209 patients were enrolled in this study (56% males; age 58.8 ± 13.3 years; age at treatment 54 ± 10.9 years). Genotype subgrouping was as follows: 1a (16%), 1b (58%), 2a (4%), 3 (18%), and 4a (2%). Overall, 71% of patients were considered treatment-naïve, with a mean follow-up time of 4.5 ± 1.3 years. Fibrosis improvement was observed among 57% of patients; fibrosis progression was seen among 7% of patients and no change was seen in 36% of patients. Moreover, 28% of these patients regressed from F3/F4 to F2 or less. In our multivariable analysis, the age at treatment and advanced fibrosis stage were found to be factors significantly associated with fibrosis regression. In conclusion, fibrosis improvement was observed among 57% of HCV patients after treatment with DAAs. Age and advanced fibrosis at baseline were found to be factors associated with fibrosis regression.https://www.mdpi.com/2075-1729/13/9/1872hepatitis Cfibrosisregressiondirect-acting antiviralFibroscan |
| spellingShingle | Naim Abu-Freha Osama Abu-Kosh David Yardeni Yaffa Ashur Muhammad Abu-Arar Baha Yousef Shulamit Monitin Sarah Weissmann Ohad Etzion Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents Life hepatitis C fibrosis regression direct-acting antiviral Fibroscan |
| title | Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents |
| title_full | Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents |
| title_fullStr | Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents |
| title_full_unstemmed | Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents |
| title_short | Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents |
| title_sort | liver fibrosis regression and associated factors in hcv patients treated with direct acting antiviral agents |
| topic | hepatitis C fibrosis regression direct-acting antiviral Fibroscan |
| url | https://www.mdpi.com/2075-1729/13/9/1872 |
| work_keys_str_mv | AT naimabufreha liverfibrosisregressionandassociatedfactorsinhcvpatientstreatedwithdirectactingantiviralagents AT osamaabukosh liverfibrosisregressionandassociatedfactorsinhcvpatientstreatedwithdirectactingantiviralagents AT davidyardeni liverfibrosisregressionandassociatedfactorsinhcvpatientstreatedwithdirectactingantiviralagents AT yaffaashur liverfibrosisregressionandassociatedfactorsinhcvpatientstreatedwithdirectactingantiviralagents AT muhammadabuarar liverfibrosisregressionandassociatedfactorsinhcvpatientstreatedwithdirectactingantiviralagents AT bahayousef liverfibrosisregressionandassociatedfactorsinhcvpatientstreatedwithdirectactingantiviralagents AT shulamitmonitin liverfibrosisregressionandassociatedfactorsinhcvpatientstreatedwithdirectactingantiviralagents AT sarahweissmann liverfibrosisregressionandassociatedfactorsinhcvpatientstreatedwithdirectactingantiviralagents AT ohadetzion liverfibrosisregressionandassociatedfactorsinhcvpatientstreatedwithdirectactingantiviralagents |